<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">DIJ</journal-id>
<journal-id journal-id-type="hwp">spdij</journal-id>
<journal-title>Therapeutic Innovation &amp; Regulatory Science</journal-title>
<issn pub-type="ppub">2168-4790</issn>
<issn pub-type="epub">2164-9200</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/2168479012471945</article-id>
<article-id pub-id-type="publisher-id">10.1177_2168479012471945</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Global Perspectives</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Effect of Market-Based Economic Factors on the Adoption of Orphan Drugs Across Multiple Countries</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Matthews</surname>
<given-names>John T.</given-names>
</name>
<degrees>MBA, PhD</degrees>
<xref ref-type="aff" rid="aff1-2168479012471945">1</xref>
<xref ref-type="corresp" rid="corresp1-2168479012471945"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Glass</surname>
<given-names>Lucas</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="aff2-2168479012471945">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-2168479012471945">
<label>1</label>Merck Pharmaceuticals, North Wales, PA, USA</aff>
<aff id="aff2-2168479012471945">
<label>2</label>Routine Recovery LLC, Philadelphia, PA, USA</aff>
<author-notes>
<corresp id="corresp1-2168479012471945">John T. Matthews, Merck Pharmaceuticals, 110 Stoneybrook Drive, Ridley Park, PA 19078, USA. Email: <email>jmatt888@gmail.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2013</year>
</pub-date>
<volume>47</volume>
<issue>2</issue>
<fpage>226</fpage>
<lpage>234</lpage>
<history>
<date date-type="received">
<day>19</day>
<month>8</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>5</day>
<month>11</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="other">Drug Information Association</copyright-holder>
</permissions>
<abstract>
<p>Orphan drugs are designed to treat rare disease. Multiple countries have approved regulations that support the creation of new orphan drugs. The regulations directly and indirectly affect orphan drug markets and contribute to classifying a country as being more or less market based. A more market-based country is recognized as functioning closest to free market principles, where the actions of supply, demand, and pricing operate with minimal government involvement. However, little information exists on how country market differences affect the adoption of these orphan drugs. This study argues that relationships exist between country market-based economic factors and the adoption of orphan drugs. This research uses a combination of qualitative and quantitative methods, drawing on orphan drug adoption of 13 marketed orphan drugs in France, Germany, Spain, the UK, and the US. Results show a statistically significant but negative relationship between the degree to which a country is market based and the adoption of orphan drugs. Results suggest that governments and regulators in less market-based countries support market factors that result in a more efficient delivery of orphan drug products to patients with rare diseases.</p>
</abstract>
<kwd-group>
<kwd>orphan drug</kwd>
<kwd>rare disease</kwd>
<kwd>adoption</kwd>
<kwd>market-based</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-2168479012471945">
<title>Introduction</title>
<p>Since 1983, the US Orphan Drug Act (ODA) has been credited with promoting the creation of more than 400 drugs for patients with rare disease in the US. Success of orphan drug regulations is often measured as the number of new products brought to market.<sup>
<xref ref-type="bibr" rid="bibr1-2168479012471945">1</xref>
</sup> However, missing from this measure is whether these drugs for rare diseases are getting to the patients for whom they are indicated. Little evidence exists to quantify the adoption of these products by patients with rare disease. This study attempts to support success by assessing orphan drug adoption across multiple countries, questioning whether systems that are more or less market based are linked to the adoption of orphan drugs.</p>
<p>Countries have different pharmaceutical regulations guiding pricing, reimbursement, distribution, and access; each adjusts these market controls, making tradeoffs in equity or efficiency.</p>
<p>Over the past several years, focus on orphan drugs has centered on high prescription prices and inherent profit opportunities for pharmaceutical developers. High prices have resulted in multiple orphan drugs achieving blockbuster status.<sup>
<xref ref-type="bibr" rid="bibr2-2168479012471945">2</xref>
</sup> The financial success of smaller developers of orphan drugs has garnered the attention of larger pharmaceutical companies experiencing declining pipelines and patent expirations. This trend has resulted in more than 400 new orphan drug compounds under development throughout the world.<sup>
<xref ref-type="bibr" rid="bibr3-2168479012471945">3</xref>
</sup> Given the expected growth of both orphan drug products and pharmaceutical regulations, this study focuses attention on determining how country-based market factors may affect orphan drug adoption.</p>
<sec id="section2-2168479012471945">
<title>Markets</title>
<p>This study recognizes a market-based economy as one in which countries function closer to a free market, where the actions of supply, demand, and pricing operate with minimal government involvement. Economic theory supports the notion that markets more closely reflecting market-based economic principles achieve greater innovations and are more efficient.<sup>
<xref ref-type="bibr" rid="bibr4-2168479012471945">4</xref>,<xref ref-type="bibr" rid="bibr5-2168479012471945">5</xref>
</sup> Studies examining relationships between market-based factors and the creation of pharmaceutical innovation suggest that government interference reduces investments in pharmaceuticals and biotechnology, thereby affecting stock prices, future research and development, and venture capital funding.<sup>
<xref ref-type="bibr" rid="bibr6-2168479012471945">6</xref>
</sup> Authors support that increased market interference results in inefficient market outcomes and health care systems.<sup>
<xref ref-type="bibr" rid="bibr7-2168479012471945">7</xref>,<xref ref-type="bibr" rid="bibr8-2168479012471945">8</xref>
</sup> However, no known research assesses whether market-based factors are linked to the adoption of new innovative orphan drugs.</p>
<p>Markets vary among countries. Research from Scott et al<sup>
<xref ref-type="bibr" rid="bibr9-2168479012471945">9</xref>
</sup> and Butler<sup>
<xref ref-type="bibr" rid="bibr10-2168479012471945">10</xref>
</sup> suggests that markets are developing and evolving only in response to consumer demands within the framework of rules, regulations, and tax incentives in which they operate. The degree to which a country is market based is supported from existing measures of market freedoms.<sup>
<xref ref-type="bibr" rid="bibr4-2168479012471945">4</xref>
</sup>
<sup>,</sup>
<sup>
<xref ref-type="bibr" rid="bibr11-2168479012471945">11</xref>
</sup> Research supports that countries with more economic freedoms attract more investments, achieve greater productivity and growth,<sup>
<xref ref-type="bibr" rid="bibr12-2168479012471945">12</xref>
</sup> and have better social outcomes, higher per-capita incomes, longer life expectancy, and lower infant mortality.<sup>
<xref ref-type="bibr" rid="bibr13-2168479012471945">13</xref>
</sup>
</p>
</sec>
<sec id="section3-2168479012471945">
<title>Pricing</title>
<p>Pharmaceutical markets and research and development investments are guided by prices and expected profits. In support of market-based pricing, Calfee<sup>
<xref ref-type="bibr" rid="bibr7-2168479012471945">7</xref>
</sup> identified the dominance of government and third-party payers as one of the forces that undermine the role of market-generated pharmaceutical prices. Calfee<sup>
<xref ref-type="bibr" rid="bibr7-2168479012471945">7</xref>
</sup> and Edwards et al<sup>
<xref ref-type="bibr" rid="bibr6-2168479012471945">6</xref>
</sup> support that movements away from market-based pricing will result in decreases in venture capital and market valuations. Authors also suggest that in the absence of market-based pricing, companies will avoid orphan drug products in pursuit of therapies with greater market potential. Measuring the degree to which pharmaceutical pricing is market based therefore supports the extent to which a free market exists in a country.</p>
</sec>
<sec id="section4-2168479012471945">
<title>Adoption</title>
<p>Adoption is defined as purchase of an orphan drug. Many authors use the terms <italic>diffusion</italic>, <italic>adoption</italic>, and <italic>access</italic> interchangeably; as supported by Rogers: “The adoption of most innovations entails the purchase of a new product, although this fact has often not been recognized by diffusion scholars.”<sup>
<xref ref-type="bibr" rid="bibr14-2168479012471945">14</xref>
</sup> For example, Dupont and Van Wilder<sup>
<xref ref-type="bibr" rid="bibr15-2168479012471945">15</xref>
</sup> analyzed access to pharmaceutical products using the marker of product reimbursement. Similarly, Varol et al<sup>
<xref ref-type="bibr" rid="bibr16-2168479012471945">16</xref>
</sup> analyzed speed of adoption by measuring product launch date.</p>
</sec>
<sec id="section5-2168479012471945">
<title>Pricing and Adoption</title>
<p>Relative prices of pharmaceutical products are frequently studied. In one study, Danzon and Taylor<sup>
<xref ref-type="bibr" rid="bibr17-2168479012471945">17</xref>
</sup> found that patients forego expensive drugs with large coinsurance or limited insurance coverage, resulting in slower adoption. In another study, Danzon et al<sup>
<xref ref-type="bibr" rid="bibr18-2168479012471945">18</xref>
</sup> found that countries with low drug prices and small market size have fewer and later drug launches. Similarly, Varol et al<sup>
<xref ref-type="bibr" rid="bibr16-2168479012471945">16</xref>
</sup> found that low prices reduced and slowed product adoption, and high product price expectation increased the speed of adoptions internationally. Examination of relative prices challenges whether adoption of orphan products is affected by price and not the degree to which a country has a market-based system.</p>
<p>Diffusion occurs differently across countries. In studies by Cohen et al,<sup>
<xref ref-type="bibr" rid="bibr19-2168479012471945">19</xref>
</sup> ‘t Hoen,<sup>
<xref ref-type="bibr" rid="bibr20-2168479012471945">20</xref>
</sup> and Morgan and Kennedy,<sup>
<xref ref-type="bibr" rid="bibr21-2168479012471945">21</xref>
</sup> authors discuss and measure barriers to accessibility, such as costs, pricing, reimbursement, and regulation of pharmaceutical products and markets. These regulatory differences challenge assumptions that countries with a more market-based system have greater adoption of pharmaceutical products.</p>
</sec>
<sec id="section6-2168479012471945">
<title>Regulations</title>
<p>Market differences across countries are often described in terms of variance among regulations. Pharmaceutical markets are highly regulated in comparison to other markets. Pharmaceutical regulations typically include pricing and reimbursement measures to contain costs or promote rational distribution and use of pharmaceutical products. Many authors have studied the effect of individual regulations and their effect on price or product diffusion. For example, McClellan and Kessler<sup>
<xref ref-type="bibr" rid="bibr22-2168479012471945">22</xref>
</sup> found that diffusion patterns of high-technology products are influenced by country regulations and payment systems to physicians and hospitals. Similarly, Hashimoto et al<sup>
<xref ref-type="bibr" rid="bibr23-2168479012471945">23</xref>
</sup> analyzed the diffusion of one medical technology across 2 hospital systems in Japan and the US, finding that diffusion differs according to country payment systems for hospitals and physicians. Research supports that insurance and country payment systems influence both the diffusion of existing technology and the expected profitability of new innovations.<sup>
<xref ref-type="bibr" rid="bibr24-2168479012471945">24</xref>
</sup>
<sup>,</sup>
<sup>
<xref ref-type="bibr" rid="bibr25-2168479012471945">25</xref>
</sup> Furthermore, Fretheim and Oxman<sup>
<xref ref-type="bibr" rid="bibr26-2168479012471945">26</xref>
</sup> and Chaix-Couturier et al<sup>
<xref ref-type="bibr" rid="bibr27-2168479012471945">27</xref>
</sup> argued that insurance incentives discourage drug adoption as prescribers are guided by regulators or insurers on what products they should be prescribing. Liu et al<sup>
<xref ref-type="bibr" rid="bibr28-2168479012471945">28</xref>
</sup> reported similar findings in Thailand, finding that even in a country with universal access to health care, profit-seeking behavior becomes a barrier to pharmaceutical adoption.</p>
<p>This study recognizes multiple factors affecting pharmaceutical product adoption. These factors may include volume of physicians, age of physicians, number of physician specialists versus general practitioners, physician involvement in clinical trials, country regulatory factors, product delays to market launch, product novelty or therapeutic importance, pharmaceutical developer size, physician and patient knowledge of disease and pharmaceutical product, advertising, patient advocacy groups, country level of development, country characteristics, and multiple other factors. Many of these factors have been studied individually with little or no reference to orphan drugs, product adoption, or variance among market-based countries.</p>
<p>These differences provide information on individual country markets, leading to 3 hypotheses: (1) Countries with more market-based economies will be associated with a greater adoption of orphan drugs. (2) Countries with more market-based pricing of pharmaceuticals will be associated with a greater adoption of orphan drugs. (3) Countries with higher relative prices of selected orphan drugs will be associated with a greater adoption of orphan drugs.</p>
</sec>
</sec>
<sec id="section7-2168479012471945" sec-type="materials|methods">
<title>Materials and Methods</title>
<p>This study uses a created data set to support analysis of hypotheses. General information on approved orphan drugs in this study was obtained from the US FDA list of designated and approved orphan drugs and the EU Office of Medicinal Products. US and EU drug-pricing information was obtained from the IMS pharmaceutical sales database and existing research studies.<sup>
<xref ref-type="bibr" rid="bibr29-2168479012471945">29</xref>
</sup>
<sup>,</sup>
<sup>
<xref ref-type="bibr" rid="bibr30-2168479012471945">30</xref>
</sup> The countries of France, Germany, Spain, the UK, and the US were selected because they are industrially and politically similar<sup>
<xref ref-type="bibr" rid="bibr5-2168479012471945">5</xref>
</sup> and represent more than 70% of all pharmaceutical sales.<sup>
<xref ref-type="bibr" rid="bibr31-2168479012471945">31</xref>
</sup> Together, the US and EU orphan drug regulators have also approved the majority of orphan drugs available in pharmaceutical markets worldwide.</p>
<p>Pharmaceutical products used for this study include 13 market-approved orphan drugs approved for 15 different indications available for purchase in study countries between January 1, 2007, and December 31, 2007. The year 2007 was chosen as a primary source due to the availability of data from existing studies.<sup>
<xref ref-type="bibr" rid="bibr29-2168479012471945">29</xref>
</sup>
</p>
<sec id="section8-2168479012471945">
<title>Variables</title>
<p>This study defines orphan drug adoption as a factor of the number of patients with a rare disease using an indicated orphan drug, compared to the number of rare disease patients likely to use that drug based on disease prevalence. The variable <italic>adoption</italic> is calculated using multiple inputs. This study extracts data on orphan drug annual cost of therapy from the Orofino et al<sup>
<xref ref-type="bibr" rid="bibr29-2168479012471945">29</xref>
</sup> study, in which the authors determined annual cost of therapy through analysis of product package inserts or the manufacturers’ recommended dosage and assumed that all patients were receiving a maintenance dose. Orofino et al<sup>
<xref ref-type="bibr" rid="bibr29-2168479012471945">29</xref>
</sup> then calculated the cost of each pharmaceutical form by dividing the price of the presentation by the number of pharmaceutical forms. By multiplying the number of pharmaceutical forms per administration by the number of administrations per year and the cost per pharmaceutical form, one obtains a mean <italic>estimated</italic>annual cost per patient for each orphan drug and indication in each of the countries studied. Cost calculations are then used to support the calculation of product adoption. An adoption calculation example is included in the <xref ref-type="app" rid="app1-2168479012471945">appendix</xref>.</p>
<p>The variable <italic>market-based country score</italic> is calculated by measuring and classifying countries based on 2 recognized measures of economic freedoms. Measures include the Index of Economic Freedoms<sup>
<xref ref-type="bibr" rid="bibr4-2168479012471945">4</xref>
</sup> and the Economic Freedoms of the World Index.<sup>
<xref ref-type="bibr" rid="bibr11-2168479012471945">11</xref>
</sup> Countries were analyzed using their year 2007 combined scores. Results identified in <xref ref-type="table" rid="table1-2168479012471945">Table 1</xref> show all scores adjusted to a 100-point scale. Combined scores support identification of a country being more market based and recognize the US as the country with the most economic freedoms, followed by the UK, Germany, Spain, and finally France.</p>
<table-wrap id="table1-2168479012471945" position="float">
<label>Table 1.</label>
<caption>
<p>Index of Economic Freedom and Freedom of the World Index scores among study countries.</p>
</caption>
<graphic alternate-form-of="table1-2168479012471945" xlink:href="10.1177_2168479012471945-table1.tif"/>
<table>
<thead>
<tr>
<th> </th>
<th>Index of Economic Freedom Score<sup>a</sup> (100-point scale)</th>
<th>Freedoms of the World Index Score<sup>b</sup>
</th>
<th>Freedoms of the World Index–Adjusted Score<sup>c</sup>
</th>
<th>Combined Study Score<sup>d</sup>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>France</td>
<td>62.1</td>
<td>7.43</td>
<td>74.3</td>
<td>136.4</td>
</tr>
<tr>
<td>Germany</td>
<td>70.8</td>
<td>7.5</td>
<td>75</td>
<td>145.8</td>
</tr>
<tr>
<td>Spain</td>
<td>69.2</td>
<td>7.32</td>
<td>73.2</td>
<td>142.4</td>
</tr>
<tr>
<td>UK</td>
<td>79.9</td>
<td>7.89</td>
<td>78.9</td>
<td>158.8</td>
</tr>
<tr>
<td>US</td>
<td>81.2</td>
<td>8.06</td>
<td>80.6</td>
<td>161.8</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-2168479012471945">
<p>
<sup>a</sup>Index of Economic Freedoms is a 100-point scale.</p>
</fn>
<fn id="table-fn2-2168479012471945">
<p>
<sup>b</sup>Freedoms of the World Index is a 10-point scale.</p>
</fn>
<fn id="table-fn3-2168479012471945">
<p>
<sup>c</sup>Freedoms of the World Index score is adjusted to a 100-point scale.</p>
</fn>
<fn id="table-fn4-2168479012471945">
<p>
<sup>d</sup>Higher numbers equal greater economic freedom.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The variable <italic>market-based pricing of pharmaceuticals</italic> is measured by comparing prices of multiple drugs across multiple Anatomical Therapeutic Chemical (ATC) groups across each country. The drug products used for this portion of analysis were pulled from a restricted sample of the 2010 list of the top 100 selling drugs from 2010<sup>
<xref ref-type="bibr" rid="bibr32-2168479012471945">32</xref>
</sup> and are identified in <xref ref-type="table" rid="table2-2168479012471945">Table 2</xref>. Data for this variable support recognition of a country as being more or less market based. Drug selection was limited by products that were approved and marketed in all analyzed countries. All competing drug product prices in the same ATC category were then analyzed for standard deviation among prices and organized by country. The expectation is that larger price variances within ATC groups identify countries exhibiting greater market-based pricing.</p>
<table-wrap id="table2-2168479012471945" position="float">
<label>Table 2.</label>
<caption>
<p>Anatomical Therapeutic Chemical (ATC) categories, ATC descriptions, and included products analyzed to calculate independent variable for hypothesis 2.</p>
</caption>
<graphic alternate-form-of="table2-2168479012471945" xlink:href="10.1177_2168479012471945-table2.tif"/>
<table>
<thead>
<tr>
<th>ATC Category</th>
<th>Description</th>
<th>Inclusive Products</th>
</tr>
</thead>
<tbody>
<tr>
<td>A2B2</td>
<td>Antiulcerants, acid pump inhibitors</td>
<td>Omeprazole, lansoprazole, pantoprazole, esomeprazole, rabeprazole</td>
</tr>
<tr>
<td>C10A1</td>
<td>Statins, HMG-CoA reductase inhibitors</td>
<td>Fluvastatin, pravastatin, simvastatin, atorvastatin, rosuvastatin, lovastatin</td>
</tr>
<tr>
<td>C9C0</td>
<td>Cardiovascular disease, angiotensin II antagonists, antihypertensives</td>
<td>Losartan, irbesartan, candesartan, olmesartan, valsartan, telmisartan, eprosartan</td>
</tr>
<tr>
<td>N6A4</td>
<td>SSRI antidepressants and anxiolytics, antidepressants</td>
<td>Fluvoxamine, paroxetine, sertraline, citalopram, escitalopram, fluoxetine</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Ranked results from analysis of standard deviations of prices between product categories and countries are reported in <xref ref-type="table" rid="table3-2168479012471945">Table 3</xref>. Combined ranks in <xref ref-type="table" rid="table3-2168479012471945">Table 3</xref> represent the US as the country with the highest standard deviations between analyzed products. Results therefore support the US as having more market-based pharmaceutical pricing, followed by Germany, the UK, Spain, and France. The data used in this variable were from 2010 and represent the extent to which a country is market based.</p>
<table-wrap id="table3-2168479012471945" position="float">
<label>Table 3.</label>
<caption>
<p>Results of ranked standard deviations of study drugs categorized by Anatomical Therapeutic Chemical (ATC) category and summarized by study country.</p>
</caption>
<graphic alternate-form-of="table3-2168479012471945" xlink:href="10.1177_2168479012471945-table3.tif"/>
<table>
<thead>
<tr>
<th>Country</th>
<th>Summary of Ranks</th>
<th>Market-Based Pricing Rank<sup>a</sup>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>France</td>
<td>21</td>
<td>1</td>
</tr>
<tr>
<td>Germany</td>
<td>14</td>
<td>4</td>
</tr>
<tr>
<td>Spain</td>
<td>18</td>
<td>2</td>
</tr>
<tr>
<td>UK</td>
<td>17</td>
<td>3</td>
</tr>
<tr>
<td>USA</td>
<td>5</td>
<td>5</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-2168479012471945">
<p>
<sup>a</sup>1 = less market based, 5 = more market based.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The variable <italic>relative prices</italic> is measured by comparing absolute prices of studied orphan drug products. Orphan products are compared by standard units, defined by IMS as standardized product variances and strengths across countries. Prices of products are obtained from IMS ex-manufacturer prices.<sup>
<xref ref-type="bibr" rid="bibr30-2168479012471945">30</xref>
</sup>
</p>
</sec>
<sec id="section9-2168479012471945">
<title>Control Variables</title>
<p>This study also considers multiple control variables, identified in <xref ref-type="table" rid="table4-2168479012471945">Table 4</xref>.</p>
<table-wrap id="table4-2168479012471945" position="float">
<label>Table 4.</label>
<caption>
<p>Study variables and descriptions.</p>
</caption>
<graphic alternate-form-of="table4-2168479012471945" xlink:href="10.1177_2168479012471945-table4.tif"/>
<table>
<thead>
<tr>
<th>Variable Name</th>
<th>Variable Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orphan Drug Adoption</td>
<td>The portion of rare disease patients who have adopted an indicated orphan drug as a portion of the total number of patients with the same indicated rare disease</td>
</tr>
<tr>
<td>Market-Based Country Score</td>
<td>Combined country scores from the Index of Economic Freedoms and the Economic Freedoms of the World Index</td>
</tr>
<tr>
<td>Market-Based Pricing of Pharmaceuticals</td>
<td>Ranking of countries exhibiting highest standard deviation of product prices across pharmaceutical Anatomical Therapeutic Chemical (ATC) categories</td>
</tr>
<tr>
<td>Relative Price</td>
<td>Absolute price of studied orphan drug products</td>
</tr>
<tr>
<td>Duration on Market</td>
<td>The time period that a drug has been on the market in relation to its market approval date<sup>
<xref ref-type="bibr" rid="bibr30-2168479012471945">30</xref>
</sup>
</td>
</tr>
<tr>
<td>Disease Prevalence</td>
<td>Rare disease prevalence for indicated orphan drug product<sup>
<xref ref-type="bibr" rid="bibr34-2168479012471945">34</xref>
</sup>
</td>
</tr>
<tr>
<td>Drug Impact Factor</td>
<td>The portion of annual sales of an orphan drug in a country in relationship to total pharmaceutical sales in that country</td>
</tr>
<tr>
<td>Speed to Launch</td>
<td>The number of days it takes a product to move from market approval until first product sold<sup>
<xref ref-type="bibr" rid="bibr30-2168479012471945">30</xref>
</sup>
</td>
</tr>
<tr>
<td>Country of Invention</td>
<td>The country location of the pharmaceutical developer of the orphan drug<sup>
<xref ref-type="bibr" rid="bibr35-2168479012471945">35</xref>,<xref ref-type="bibr" rid="bibr36-2168479012471945">36</xref>
</sup>
</td>
</tr>
<tr>
<td>Number of Patient Advocacy Groups</td>
<td>The number of patient advocacy groups supporting a given rare disease or condition, as related to the studied orphan drug<sup>
<xref ref-type="bibr" rid="bibr37-2168479012471945">37</xref>,<xref ref-type="bibr" rid="bibr38-2168479012471945">38</xref>
</sup>
</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section10-2168479012471945">
<title>Statistical Methods</title>
<p>This study uses linear regression with a log-transformed outcome variable to analyze relationships between variables.<sup>
<xref ref-type="bibr" rid="bibr33-2168479012471945">33</xref>
</sup> Study sample size is 13 orphan drug products for 15 different disease indications across 5 countries, thus resulting in 75 cases.</p>
<p>Before choosing our model and analyzing our covariates, we examined several different models such as Y<sup>2</sup>, Y<sup>.5</sup>, Y, and finally ln(Y). We were able to maximize the <italic>R</italic><sup>2</sup> value with the ln(Y) model. This method along with the visual confirmation from the scatter plot (results) suggests that the linear regression with a log link was appropriate for our analysis. The scatter plot identified in <xref ref-type="fig" rid="fig1-2168479012471945">Figure 1</xref> demonstrates a linear relationship between the ln(adoption) and market score.</p>
<fig id="fig1-2168479012471945" position="float">
<label>Figure 1.</label>
<caption>
<p>Natural log of adoption as a function of market-based country score.</p>
</caption>
<graphic xlink:href="10.1177_2168479012471945-fig1.tif"/>
</fig>
<p>The multiple regression equation is as follows:<disp-formula id="disp-formula1-2168479012471945">
<mml:math id="mml-disp1-2168479012471945">
<mml:mrow>
<mml:mtable columnalign="right left" columnspacing="thickmathspace" displaystyle="true" rowspacing=".5em">
<mml:mtr>
<mml:mtd>
<mml:mrow>
<mml:mrow>
<mml:mi mathvariant="normal">N</mml:mi>
<mml:mi mathvariant="normal">a</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mi mathvariant="normal">u</mml:mi>
<mml:mi mathvariant="normal">r</mml:mi>
<mml:mi mathvariant="normal">a</mml:mi>
<mml:mi mathvariant="normal">l</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mi mathvariant="normal">L</mml:mi>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">g</mml:mi>
</mml:mrow>
</mml:mrow>
<mml:mfenced close=")" open="(">
<mml:mrow>
<mml:mrow>
<mml:mrow>
<mml:mi mathvariant="normal">P</mml:mi>
<mml:mi mathvariant="normal">r</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mi mathvariant="normal">d</mml:mi>
<mml:mi mathvariant="normal">i</mml:mi>
<mml:mi mathvariant="normal">c</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mi mathvariant="normal">d</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mi mathvariant="normal">A</mml:mi>
<mml:mi mathvariant="normal">d</mml:mi>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">p</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mi mathvariant="normal">i</mml:mi>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">n</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">f</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mi mathvariant="normal">O</mml:mi>
<mml:mi mathvariant="normal">r</mml:mi>
<mml:mi mathvariant="normal">p</mml:mi>
<mml:mi mathvariant="normal">h</mml:mi>
<mml:mi mathvariant="normal">a</mml:mi>
<mml:mi mathvariant="normal">n</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mi mathvariant="normal">D</mml:mi>
<mml:mi mathvariant="normal">r</mml:mi>
<mml:mi mathvariant="normal">u</mml:mi>
<mml:mi mathvariant="normal">g</mml:mi>
<mml:mi mathvariant="normal">s</mml:mi>
</mml:mrow>
</mml:mrow>
</mml:mrow>
</mml:mfenced>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd>
<mml:mo stretchy="false">=</mml:mo>
<mml:msub>
<mml:mi>b</mml:mi>
<mml:mn>0</mml:mn>
</mml:msub>
<mml:mo stretchy="false">+</mml:mo>
<mml:mrow>
<mml:mrow>
<mml:mi mathvariant="normal">S</mml:mi>
<mml:mi mathvariant="normal">u</mml:mi>
<mml:mi mathvariant="normal">m</mml:mi>
<mml:mi mathvariant="normal">m</mml:mi>
<mml:mi mathvariant="normal">a</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mi mathvariant="normal">i</mml:mi>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">n</mml:mi>
</mml:mrow>
</mml:mrow>
<mml:mfenced close="]" open="[">
<mml:mrow>
<mml:msub>
<mml:mi>b</mml:mi>
<mml:mrow>
<mml:mrow>
<mml:mi mathvariant="normal">n</mml:mi>
</mml:mrow>
</mml:mrow>
</mml:msub>
<mml:msub>
<mml:mi>V</mml:mi>
<mml:mrow>
<mml:mrow>
<mml:mi mathvariant="normal">n</mml:mi>
</mml:mrow>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:mfenced>
<mml:mo stretchy="false">+</mml:mo>
<mml:mi>e</mml:mi>
<mml:mo stretchy="false">,</mml:mo>
</mml:mtd>
</mml:mtr>
</mml:mtable>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula1-2168479012471945" xlink:href="10.1177_2168479012471945-eq1.tif"/>
</disp-formula>
</p>
<p>where <italic>b</italic>
<sub>0</sub> is the constant adoption of orphan drugs independent of price and annual orphan drug cost, <italic>b</italic>
<sub>n</sub> is the change in adoption of orphan drugs associated with unit change in the <italic>n</italic>th variable, <italic>V</italic>
<sub>n</sub> is one of the variables listed in <xref ref-type="table" rid="table4-2168479012471945">Table 4</xref>, and <italic>e</italic> is the error term.</p>
</sec>
</sec>
<sec id="section11-2168479012471945">
<title>Results</title>
<p>Descriptive statistics show 71 total cases for analysis. Data for the drug bosentan were not analyzed in the 4 EU countries given the finding of a second marketing indication for this product in these countries. Descriptive statistics in <xref ref-type="table" rid="table5-2168479012471945">Table 5</xref> display the number of cases, minimum and maximum values, and standard deviations.</p>
<table-wrap id="table5-2168479012471945" position="float">
<label>Table 5.</label>
<caption>
<p>Descriptive statistics.</p>
</caption>
<graphic alternate-form-of="table5-2168479012471945" xlink:href="10.1177_2168479012471945-table5.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>No.<sup>a</sup>
</th>
<th>Minimum</th>
<th>Maximum</th>
<th>Mean</th>
<th>Standard Deviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adoption</td>
<td>71</td>
<td>0.15%</td>
<td>18.38%</td>
<td>4.35%</td>
<td>3.97%</td>
</tr>
<tr>
<td>Mrkt_base_Ctry_scores</td>
<td>71</td>
<td>69.53</td>
<td>89.80</td>
<td>80.53</td>
<td>7.59</td>
</tr>
<tr>
<td>Mrkt_base_Pric_rank</td>
<td>71</td>
<td>1</td>
<td>5</td>
<td>3.0</td>
<td>1.4</td>
</tr>
<tr>
<td>Cost_Stand_Unit</td>
<td>71</td>
<td>$1.05</td>
<td>$1008.88</td>
<td>$174.69</td>
<td>$244.45</td>
</tr>
<tr>
<td>Dis_Preval per 100,000 population</td>
<td>71</td>
<td>0.94</td>
<td>35.80</td>
<td>10.64</td>
<td>10.97</td>
</tr>
<tr>
<td>Days_on_Market</td>
<td>71</td>
<td>42</td>
<td>3926</td>
<td>1098</td>
<td>818</td>
</tr>
<tr>
<td>Number_of_support_groups<sup>b</sup>
</td>
<td>66</td>
<td>1</td>
<td>10</td>
<td>3.5</td>
<td>1.9</td>
</tr>
<tr>
<td>Country_of_Invention</td>
<td>71</td>
<td>0.0</td>
<td>1.0</td>
<td>0.127</td>
<td>0.3229</td>
</tr>
<tr>
<td>Days_to_launch</td>
<td>71</td>
<td>–869<sup>c</sup>
</td>
<td>1574</td>
<td>174</td>
<td>335</td>
</tr>
<tr>
<td>Drug_impact_factor</td>
<td>71</td>
<td>0E-10</td>
<td>.0013148197</td>
<td>.0001841455</td>
<td>.0002466245</td>
</tr>
<tr>
<td>Valid n (listwise)</td>
<td>66</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-2168479012471945">
<p>
<sup>a</sup>Data for the drug bosentan were not analyzed in the 4 EU countries.</p>
</fn>
<fn id="table-fn7-2168479012471945">
<p>
<sup>b</sup>Some diseases had no support groups.</p>
</fn>
<fn id="table-fn8-2168479012471945">
<p>
<sup>c</sup>France’s regulations include an Authorization for Temporary Use program that provides patient access to drugs, prior to marketing approval, when a disease is considered severe and no alternative therapy is available.
</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Results show that adoption rates ranged from 0.15% to 18.4% with a mean of 4.35% and a standard deviation of 3.97%. Adoption rates recognize the percentage of the rare disease population in a specific country who were estimated to have taken an indicated orphan drug during 2007. Market-based country scores range from 69.53 to 89.8 (standard deviation, 7.59).</p>
<p>Results of hypothesis 1 linear regression with log-link model are shown in <xref ref-type="table" rid="table6-2168479012471945">Table 6</xref>.</p>
<table-wrap id="table6-2168479012471945" position="float">
<label>Table 6.</label>
<caption>
<p>Coefficients: Hypothesis 1.</p>
</caption>
<graphic alternate-form-of="table6-2168479012471945" xlink:href="10.1177_2168479012471945-table6.tif"/>
<table>
<thead>
<tr>
<th rowspan="2"> </th>
<th colspan="2">Unstandardized Coefficients</th>
<th colspan="2">Standardized Coefficients</th>
<th rowspan="2">
<italic>P</italic>
</th>
</tr>
<tr>
<th>B</th>
<th>Standard Error</th>
<th>β</th>
<th>
<italic>t</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Constant)</td>
<td>–.341</td>
<td>1.427</td>
<td>
</td>
<td>–0.239</td>
<td>.812</td>
</tr>
<tr>
<td>Mrkt_base_Ctry_scores</td>
<td>–.041</td>
<td>.018</td>
<td>–.288</td>
<td>–2.270</td>
<td>.027</td>
</tr>
<tr>
<td>Dis_Preval</td>
<td>–.015</td>
<td>.012</td>
<td>–.155</td>
<td>–1.216</td>
<td>.229</td>
</tr>
<tr>
<td>Cost_Stand_Unit</td>
<td>–.001</td>
<td>.001</td>
<td>–.138</td>
<td>–1.143</td>
<td>.258</td>
</tr>
<tr>
<td>Days_on_Market</td>
<td>.000</td>
<td>.000</td>
<td>.107</td>
<td>0.957</td>
<td>.342</td>
</tr>
<tr>
<td>Number_of_support_groups</td>
<td>–.093</td>
<td>.060</td>
<td>–.172</td>
<td>–1.566</td>
<td>.123</td>
</tr>
<tr>
<td>Country_of_Invention</td>
<td>.292</td>
<td>.403</td>
<td>.090</td>
<td>0.725</td>
<td>.472</td>
</tr>
<tr>
<td>Days_to_launch</td>
<td>.000</td>
<td>.000</td>
<td>–.063</td>
<td>–0.512</td>
<td>.611</td>
</tr>
<tr>
<td>Drug_impact_factor</td>
<td>1954.998</td>
<td>545.231</td>
<td>.459</td>
<td>3.586</td>
<td>.001</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>The results show a statistically significant negative relationship at the .05 level among a country’s market-based score and orphan drug adoption. Results also show a statistically significant relationship at the .05 level between drug impact factor and adoption of orphan drugs. No relationships were identified between the control variables of disease prevalence, drug cost per standard unit, the number of days a product has been on the market, the country of orphan drug invention, and the speed of a product to launch.</p>
<p>Results of hypothesis 2 linear regression with log-link model are shown in <xref ref-type="table" rid="table7-2168479012471945">Table 7</xref>. The results show no statistically significant relationship between country market-based pharmaceutical pricing rank and orphan drug adoption. However, a negative relationship does exist just above the .10 threshold. Results also show a statistically significant relationship of .0001 between drug impact factor and adoption of orphan drugs, and a marginally significant relationship between the number of support groups at the .06 level. In addition, results show no statistically significant relationship between the control variables of disease prevalence, drug cost per standard unit, the number of days a product has been on the market, the country of orphan drug invention, and the speed of a product to launch.</p>
<table-wrap id="table7-2168479012471945" position="float">
<label>Table 7.</label>
<caption>
<p>Coefficients: Hypothesis 2.</p>
</caption>
<graphic alternate-form-of="table7-2168479012471945" xlink:href="10.1177_2168479012471945-table7.tif"/>
<table>
<thead>
<tr>
<th rowspan="2"> </th>
<th colspan="2">Unstandardized Coefficients</th>
<th colspan="2">Standardized Coefficients</th>
<th rowspan="2">
<italic>P</italic>
</th>
</tr>
<tr>
<th>B</th>
<th>Standard Error</th>
<th>β</th>
<th>
<italic>t</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Constant)</td>
<td>–3.080</td>
<td>.438</td>
<td>
</td>
<td>–7.035</td>
<td>.000</td>
<td>
</td>
</tr>
<tr>
<td>Mrkt_base_Pric_rank</td>
<td>–.158</td>
<td>.097</td>
<td>–.210</td>
<td>–1.630</td>
<td>.109</td>
<td>
</td>
</tr>
<tr>
<td>Dis_Preval</td>
<td>–.018</td>
<td>.012</td>
<td>–.187</td>
<td>–1.457</td>
<td>.151</td>
<td>
</td>
</tr>
<tr>
<td>Cost_Stand_Unit</td>
<td>.000</td>
<td>.001</td>
<td>–.109</td>
<td>–0.888</td>
<td>.378</td>
<td>
</td>
</tr>
<tr>
<td>Days_on_Market</td>
<td>.000</td>
<td>.000</td>
<td>.117</td>
<td>1.01</td>
<td>.317</td>
<td>
</td>
</tr>
<tr>
<td>Number_of_support_groups</td>
<td>–.116</td>
<td>.060</td>
<td>–.213</td>
<td>–1.915</td>
<td>.060</td>
<td>
</td>
</tr>
<tr>
<td>Country_of_Invention</td>
<td>.200</td>
<td>.416</td>
<td>.062</td>
<td>0.480</td>
<td>.633</td>
<td>
</td>
</tr>
<tr>
<td>Days_to_launch</td>
<td>.000</td>
<td>.000</td>
<td>–.130</td>
<td>–1.062</td>
<td>.293</td>
<td>
</td>
</tr>
<tr>
<td>Drug_impact_factor</td>
<td>2218.195</td>
<td>535.648</td>
<td>.520</td>
<td>4.141</td>
<td>.0001</td>
<td>
</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Analysis of hypothesis 3 is conducted via direct assessment of studied orphan drug product prices by country. Results of linear regression with log-link model are shown in <xref ref-type="table" rid="table8-2168479012471945">Table 8</xref>. According to the results, these is no statistically significant relationship at the .05 level between orphan drug adoption and relative drug prices. The results also show no statistically significant relationships between the control variables of disease prevalence, the number of days a product has been on the market, the number of support groups for a drug’s indicated disease, the country of orphan drug invention, and the speed of a product to launch.</p>
<table-wrap id="table8-2168479012471945" position="float">
<label>Table 8.</label>
<caption>
<p>Coefficients: Hypothesis 3.</p>
</caption>
<graphic alternate-form-of="table8-2168479012471945" xlink:href="10.1177_2168479012471945-table8.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">
</th>
<th colspan="2">Unstandardized Coefficients</th>
<th colspan="2">Standardized Coefficients</th>
<th rowspan="2">
<italic>P</italic>
</th>
</tr>
<tr>
<th>B</th>
<th>Standard Error</th>
<th>β</th>
<th>
<italic>t</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Constant)</td>
<td>–3.477</td>
<td>.369</td>
<td>
</td>
<td>–9.429</td>
<td>.000</td>
</tr>
<tr>
<td>Cost_Stand_Unit</td>
<td>.000</td>
<td>.001</td>
<td>–.105</td>
<td>–0.846</td>
<td>.401</td>
</tr>
<tr>
<td>Dis_Preval</td>
<td>–.020</td>
<td>.012</td>
<td>–.212</td>
<td>–1.635</td>
<td>.107</td>
</tr>
<tr>
<td>Days_on_Market</td>
<td>.000</td>
<td>.000</td>
<td>.076</td>
<td>0.666</td>
<td>.508</td>
</tr>
<tr>
<td>Number_of_support_groups</td>
<td>–.111</td>
<td>.061</td>
<td>–.204</td>
<td>–1.812</td>
<td>.075</td>
</tr>
<tr>
<td>Country_of_Invention</td>
<td>–.114</td>
<td>.374</td>
<td>–.035</td>
<td>–0.304</td>
<td>.762</td>
</tr>
<tr>
<td>Days_to_launch</td>
<td>.000</td>
<td>.000</td>
<td>–.122</td>
<td>–0.983</td>
<td>.330</td>
</tr>
<tr>
<td>Drug_impact_factor</td>
<td>2316.717</td>
<td>539.781</td>
<td>.544</td>
<td>4.292</td>
<td>.00007</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Study results do show a significant relationship between orphan drug adoption and drug impact factor (the financial burden of a single orphan product in relation to a country’s total pharmaceutical costs). However, the value of this variable is questioned for all 3 hypotheses. The variable is calculated as a percentage of potential sales of orphan drugs divided by actual country annual sales. Therefore, there is a direct mathematical relationship showing that as adoption increases, the drug impact factor will increase. Likewise, the variable would be statistically significant no matter what country had a higher adoption rate. Therefore, this variable has limited significance and we cannot generalize information from this result.</p>
</sec>
<sec id="section12-2168479012471945">
<title>Discussion</title>
<p>A review of study results and literature suggests that several prevailing factors affect the outcomes of this study. These factors include society’s valuation of patients with rare disease and government’s involvement in and support of orphan drug markets. These factors combine to support the idea that orphan drug markets are so different that traditional market-based mechanisms are very limited or nonexistent in this marketplace.</p>
<sec id="section13-2168479012471945">
<title>Societal Valuation and Government Involvement</title>
<p>A greater adoption of orphan drugs in less market-based populations supports the conclusion that countries place more importance on equity versus concern for an efficient pharmaceutical market. This has been described by Millar et al<sup>
<xref ref-type="bibr" rid="bibr41-2168479012471945">41</xref>
</sup> and Ferner and Hughes<sup>
<xref ref-type="bibr" rid="bibr40-2168479012471945">40</xref>
</sup> as overvaluing patients or supporting special status of patients with rare disease at the expense of patients with more common diseases. Patients, caregivers, and concerned family members support special status as they lobby for and receive funding, new regulations, and special access for rare disease products and orphan drug markets.<sup>
<xref ref-type="bibr" rid="bibr42-2168479012471945">42</xref><xref ref-type="bibr" rid="bibr43-2168479012471945"/>–<xref ref-type="bibr" rid="bibr44-2168479012471945">44</xref>
</sup> These supportive actions may indirectly influence the adoption of these new drugs by patients with rare diseases. Therefore, it is likely that society itself influences countries to implement regulatory actions for rare disease patients. As a result, countries are directly involved in developing, approving, and regulating orphan drug products and markets. Regulations for orphan products result in encouraging pharmaceutical company investments in new product innovations for those with rare diseases. It is therefore possible that countries enact legislation that encourages innovations and unintentionally support product adoption.</p>
<p>Legislative actions also influence country payment and insurance mechanisms. Product adoption is thereby influenced by the wide variety of insurance and payment mechanisms among countries. This position is supported by the Institute of Medicine report <italic>Rare Diseases and Orphan Products</italic>,<sup>
<xref ref-type="bibr" rid="bibr45-2168479012471945">45</xref>
</sup> which found that some insurance mechanisms result in the unintended consequence of discouraging product adoption. Other studies support that insurance cost-sharing mechanisms have an effect on product use.<sup>
<xref ref-type="bibr" rid="bibr46-2168479012471945">46</xref>
</sup>
<sup>,</sup>
<sup>
<xref ref-type="bibr" rid="bibr47-2168479012471945">47</xref>
</sup> Results may therefore be challenged by the recognition that insurance and reimbursement mechanisms may be the primary factor affecting orphan drug adoption in a country. However, these same mechanisms vary across countries with more market freedoms compared with those with fewer market freedoms.</p>
<p>Results show that market-based pricing was not related to orphan drug adoption. Results do, however, provide directional support for less market-based country pricing of pharmaceuticals having a relationship to orphan drug adoption. When results are combined with hypothesis 1, the variables jointly support the greater research question that identifies a relationship between orphan drug adoption and a country identification as being less market based. Results support that the actions of governments and regulators can affect a greater adoption of pharmaceuticals by rare disease patients. In the case of orphan drugs, governments are, in effect, structuring rules so that orphan drug products can make it to market. In contrast, other non–orphan drug products operate within the existing rules and regulations and adapt to the market structure created for them.</p>
<p>Combined, these factors mask the traditional role that pricing, information, and other market factors play in purchasing decisions. Results support that orphan drugs and the orphan drug market are so different that little free market-based activity occurs. As a result, it is not surprising that countries with a less market-based system may actually provide more incentives that result in a greater adoption of orphan drug products by rare disease patients.</p>
</sec>
<sec id="section14-2168479012471945">
<title>Limitations</title>
<p>Limitations for this study include the possibility that not enough diverse countries were selected for analysis. Use of 4 similarly aligned EU countries along with the US, which has a significantly varied insurance and payment structure, challenges the validity of the results. Future research will be needed to discern whether differences were primarily attributable to reimbursement mechanisms rather than market freedoms.</p>
<p>This study recognizes that orphan drug products studied were not randomly selected. This study recognizes that direct measurement of patient consumption of orphan products is the best measurement of product adoption. The next best alternative used by this study and others includes analysis of sales data. The IMS sales database, however, lacks manufacturer discounting data. Lack of discounting data for all countries may have led to overestimation of prices and product consumption in this study. Data collection methods may also pose a risk to data due to drug sampling variance across countries.</p>
<p>This study assumes that disease prevalence for a specific disease is consistent across all study countries. The Orphanet prevalence database<sup>
<xref ref-type="bibr" rid="bibr47-2168479012471945">47</xref>
</sup> does not capture prevalence nuances between countries but is considered a valid source of prevalence information used in multiple research studies.<sup>
<xref ref-type="bibr" rid="bibr45-2168479012471945">45</xref>
</sup> This study also assumes that only patients with an indicated rare disease consume an orphan drug product. Yet patients without a specific indicated rare disease diagnosis may have received one of the study medications off label.</p>
<p>Patient advocacy group data used to assess number of groups proved unreliable. This is based on the fact that no centralized organization has a comprehensive database of support groups. Finally, this study uses data from 2007 because of availability of certain data. The adoption of orphan drug products has likely changed since 2007 given the growth of drug company–sponsored patient access programs and continual changes in country regulations for pharmaceutical insurance/payment mechanisms.</p>
<p>The support for variable 2 (market-based pricing) was drawn from 2010 data, whereas the dependent variable of adoption in this study was pulled from 2007 data. The years 2007 and 2010 also saw changes in worldwide economic status of most countries. As a result, the authors concede that even though variable 1 market-based scores support variable 2 findings of the US as most market based, and France and Spain as least market based, it is possible that positional changes between Germany and the UK could be of consequence and could have also shown market-based pricing to be a significant factor affecting the adoption of orphan drugs along with market-based country scores.</p>
</sec>
<sec id="section15-2168479012471945">
<title>Future Research</title>
<p>Investigators seeking to confirm results should consider using more orphan drugs and a greater range of high and low market-based countries. It is also possible that orphan drug adoption is related to certain market actions occurring in countries considered less market based. Future research should attempt to identify what specific market aspects promote orphan drug adoption. Considerations could include focused research on variances among insurance models or country payment mechanisms. Although results are representative of an orphan drug market, future research should consider whether results translate to a non–orphan drug market.</p>
</sec>
</sec>
<sec id="section16-2168479012471945">
<title>Conclusions</title>
<p>This study examines the adoption of orphan drugs in countries considered more or less market based. Results show that a statistically significant negative relationship exists between orphan drug adoption and the degree to which a country is market based. Results also support a negative nonsignificant relationship among market-based pricing of pharmaceutical products and the adoption of orphan drugs. The study’s results are unsurprising given that orphan drugs and orphan drug markets are different from non–orphan drug products. Orphan drug products are largely supported by governmental regulations and incentives designed to stimulate research and create new innovative drug products, receiving benefits not typically extended to non–orphan drug products. Results also support that in the case of orphan drugs, less market-based countries interact in ways that are more supportive of the adoption of orphan products compared with more market-based countries.</p>
</sec>
</body>
<back>
<app-group>
<app id="app1-2168479012471945">
<title>Appendix. <bold>Example calculation of adoption.</bold>
</title>
<p>Sales of the drug busulfan in France in 2007 were equal to US$2,992,538 (from IMS Health sales data). Busulfan is an orphan drug product indicated for conditioning treatment prior to hematopoietic progenitor cell transplantation (FDA and EMA orphan drug database). It is estimated that there are 6.55 persons with this disease per 100,000 populations (prevalence for this disease will be 6.55 persons per 100,000 from the Orphanet prevalence database); in 2007, the population of France was 61,037,510 persons. Calculating population divided by groups of 100,000 population and multiplying by number of persons per 100,000 population gives (61,037,510/100,000) × 6.55 = 3998 affected persons. The annual cost of busulfan is US$6340.16. Multiply affected persons by annual cost (3998 × $6340.16) and the result is US$25,347,686 in expected sales if everyone in France with this disease is receiving treatment. If we then divide actual sales by predicted 2007 sales (2,992,538/25,347,686), the result is 0.118, or 11.8%. Stated differently, there is approximately 12% adoption of busulfan in France.</p>
</app>
</app-group>
<fn-group>
<fn fn-type="conflict" id="fn1-2168479012471945">
<label>Declaration of Conflicting Interests</label>
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-2168479012471945">
<label>Funding</label>
<p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-2168479012471945">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haffner</surname>
<given-names>ME</given-names>
</name>
</person-group>. <article-title>Orphan drug product regulation—United States</article-title>. <source>Int J Clin Pharmacol Ther</source>. <year>2002</year>;<volume>40</volume>(<issue>2</issue>):<fpage>84</fpage>–<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr2-2168479012471945">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cutler</surname>
<given-names>DM</given-names>
</name>
</person-group>. <article-title>The demise of the blockbuster?</article-title> <source>N Engl J Med</source>. <year>2007</year>;<volume>356</volume>(<issue>13</issue>):<fpage>1292</fpage>–<lpage>1293</lpage>.</citation>
</ref>
<ref id="bibr3-2168479012471945">
<label>3</label>
<citation citation-type="book">
<collab collab-type="author">Pharmaceutical Research and Manufacturers of America</collab>. <article-title>More than 400 medicines in development to treat or prevent rare diseases</article-title>. In <source>2011 Orphan Drugs in Development for Rare Diseases</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>Pharmaceutical Research and Manufacturers of America</publisher-name>; <fpage>1</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr4-2168479012471945">
<label>4</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Miller</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>K</given-names>
</name>
</person-group>. <source>2010 Index of Economic Freedom</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>The Heritage Foundation</publisher-name>; <year>2010</year>.</citation>
</ref>
<ref id="bibr5-2168479012471945">
<label>5</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Sala-i-Martin</surname>
<given-names>X</given-names>
</name>
</person-group>. <source>The Global Competitiveness Report 2010-2011</source>. <person-group person-group-type="editor">
<name>
<surname>K</surname>
<given-names>Schwab</given-names>
</name>
</person-group>, ed. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Economic Forum</publisher-name>; <year>2010</year>.</citation>
</ref>
<ref id="bibr6-2168479012471945">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Edwards</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Armian-Hawley</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</name>
</person-group>. <article-title>The relationship between market-based pricing and biopharmaceutical innovation</article-title>. <source>Manag Care</source>. <year>2004</year>;<volume>13</volume>(<issue>6 suppl</issue>):<fpage>23</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr7-2168479012471945">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calfee</surname>
<given-names>JE</given-names>
</name>
</person-group>. <article-title>The increasing necessity for market-based pharmaceutical prices</article-title>. <source>Pharmacoeconomics</source>. <year>2000</year>;<volume>18</volume>(<issue>suppl 1</issue>):<fpage>47</fpage>–<lpage>57</lpage>.</citation>
</ref>
<ref id="bibr8-2168479012471945">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nichols</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Ginsburg</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Berenson</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Christianson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hurley</surname>
<given-names>RE</given-names>
</name>
</person-group>. <article-title>Are market forces strong enough to deliver efficient health care systems? Confidence is waning</article-title>. <source>Health Affairs</source>. <year>2004</year>;<volume>23</volume>(<issue>2</issue>):<fpage>8</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr9-2168479012471945">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scott</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Solomon</surname>
<given-names>S</given-names>
</name>
<name>
<surname>McGowan</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Applying economic principles to health care</article-title>. <source>Emerg Infec Dis</source>. <year>2001</year>;<volume>7</volume>(<issue>2</issue>):<fpage>282</fpage>–<lpage>285</lpage>.</citation>
</ref>
<ref id="bibr10-2168479012471945">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butler</surname>
<given-names>SM</given-names>
</name>
</person-group>. <article-title>A new policy framework for health care markets</article-title>. <source>Health Aff (Millwood)</source>. <year>2004</year>;<volume>23</volume>(<issue>2</issue>):<fpage>22</fpage>–<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr11-2168479012471945">
<label>11</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Gwartney</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lawson</surname>
<given-names>R.</given-names>
</name>
</person-group> <article-title>2010 economic freedom dataset</article-title>. In: <source>Economic Freedom of the World: 2011 Annual Report</source>. <year>2011</year>:<fpage>1</fpage>–<lpage>221</lpage>.</citation>
</ref>
<ref id="bibr12-2168479012471945">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hanke</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Walters</surname>
<given-names>SJ</given-names>
</name>
</person-group>. <article-title>Economic freedom, prosperity, and equality: a survey</article-title>. <source>Cato J</source>. <year>1997</year>;<volume>17</volume>(<issue>2</issue>):<fpage>117</fpage>–<lpage>146</lpage>.</citation>
</ref>
<ref id="bibr13-2168479012471945">
<label>13</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Chauffour</surname>
<given-names>J-P</given-names>
</name>
</person-group>. <source>On the Relevance of Freedom and Entitlement in Development: New Empirical Evidence (1975–2007)</source>. <comment>Policy Research Working Paper 5660. The World Bank, Poverty Reduction and Economic Management Network, International Trade Department</comment>; <year>2011</year>; <volume>1</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>37</lpage>.</citation>
</ref>
<ref id="bibr14-2168479012471945">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rogers</surname>
<given-names>EM</given-names>
</name>
</person-group>. <article-title>New product adoption and diffusion</article-title>. <source>J Consum Res</source>. <year>1976</year>;<volume>2</volume>(<issue>4</issue>):<fpage>290</fpage>–<lpage>301</lpage>.</citation>
</ref>
<ref id="bibr15-2168479012471945">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dupont</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Van Wilder</surname>
<given-names>PB</given-names>
</name>
</person-group>. <article-title>Access to orphan drugs despite poor quality of clinical evidence</article-title>. <source>Br J Clin Pharmacol</source>. <year>2011</year>;<volume>71</volume>(<issue>4</issue>):<fpage>488</fpage>–<lpage>496</lpage>.</citation>
</ref>
<ref id="bibr16-2168479012471945">
<label>16</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Varol</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Costa-i-Font</surname>
<given-names>J</given-names>
</name>
<name>
<surname>McGuire</surname>
<given-names>A.</given-names>
</name>
</person-group> <source>Explaining Early Adoption on New Medicines: Regulation, Innovation and Scale</source>. <comment>CESIFO Working Paper No. 3459. 2011</comment>: <fpage>1</fpage>–<lpage>32</lpage>.</citation>
</ref>
<ref id="bibr17-2168479012471945">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Danzon</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Drug pricing and value in oncology</article-title>. <source>Oncologist</source>. <year>2010</year>;<volume>15</volume>(<issue>suppl 1</issue>):<fpage>24</fpage>–<lpage>31</lpage>.</citation>
</ref>
<ref id="bibr18-2168479012471945">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Danzon</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>YR</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>The impact of price regulation on the launch delay of new drugs—evidence from twenty-five major markets in the 1990’s</article-title>. <source>Health Econ</source>. <year>2005</year>;<volume>14</volume>(<issue>3</issue>):<fpage>269</fpage>–<lpage>292</lpage>.</citation>
</ref>
<ref id="bibr19-2168479012471945">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Faden</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Predaris</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Patient access to pharmaceuticals: an international comparison</article-title>. <source>Eur J Health Econ</source>. <year>2007</year>;<volume>8</volume>(<issue>3</issue>):<fpage>253</fpage>–<lpage>266</lpage>.</citation>
</ref>
<ref id="bibr20-2168479012471945">
<label>20</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>‘t Hoen</surname>
<given-names>E</given-names>
</name>
</person-group>. <source>The Global Politics of Pharmaceutical Monopoly Power: Drug Patents, Access, Innovation and the Application of the WTO Doha Declaration on TRIPS and Public Health</source>. <comment>AMB Publishers</comment>; <year>2009</year> :1–136.</citation>
</ref>
<ref id="bibr21-2168479012471945">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morgan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Prescription drug accessibility and affordability in the United States and abroad</article-title>. <source>Issue Brief (Commonw Fund)</source>. <year>2010</year>;<volume>89</volume>:<fpage>1</fpage>–<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr22-2168479012471945">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McClellan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kessler</surname>
<given-names>D</given-names>
</name>
<name>
<surname>TECH</surname>
<given-names>Investigators</given-names>
</name>
</person-group>. <article-title>A global analysis of technological change in health care: the case of heart attacks</article-title>. <source>Health Aff(Millwood)</source>. <year>1999</year>;<volume>18</volume>(<issue>3</issue>):<fpage>250</fpage>–<lpage>255</lpage>.</citation>
</ref>
<ref id="bibr23-2168479012471945">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hashimoto</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Noguchi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Heidenreich</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>The diffusion of medical technology, local conditions, and technology re-invention: a comparative case study on coronary stenting</article-title>. <source>Health Policy</source>, <year>2006</year>;<volume>79</volume>(<issue>2-3</issue>):<fpage>221</fpage>–<lpage>230</lpage>.</citation>
</ref>
<ref id="bibr24-2168479012471945">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Newhouse</surname>
<given-names>JP</given-names>
</name>
</person-group>. <article-title>The erosion of the medical marketplace</article-title>. <source>Adv Health Econ Health Serv Res</source>. <year>1981</year>;<volume>2</volume>:<fpage>1</fpage>–<lpage>34</lpage>.</citation>
</ref>
<ref id="bibr25-2168479012471945">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Newhouse</surname>
<given-names>JP</given-names>
</name>
</person-group>. <article-title>Has the erosion of the medical marketplace ended?</article-title> <source>J Health Polit Policy Law</source>. <year>1988</year>;<volume>13</volume>(<issue>2</issue>):<fpage>263</fpage>–<lpage>278</lpage>.</citation>
</ref>
<ref id="bibr26-2168479012471945">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fretheim</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Oxman</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>International variation in prescribing antihypertensive drugs: its extent and possible explanations</article-title>. <source>BMC Health Serv Res</source>. <year>2005</year>;<volume>5</volume>(<issue>1</issue>):<fpage>21</fpage>.</citation>
</ref>
<ref id="bibr27-2168479012471945">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chaix-Couturier</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Durand-Zaleski</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Jolly</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Durieux</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Effects of financial incentives on medical practice: results from a systemic review of the literature and methodological issues</article-title>. <source>Int J Qual Health Care</source>. <year>2000</year>;<volume>12</volume>(<issue>2</issue>):<fpage>133</fpage>–<lpage>142</lpage>.</citation>
</ref>
<ref id="bibr28-2168479012471945">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y-M</given-names>
</name>
<name>
<surname>Kao Yang</surname>
<given-names>Y-H</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>C-R</given-names>
</name>
</person-group>. <article-title>The determinants of the adoption of pharmaceutical innovation: evidence from Taiwan</article-title>. <source>Soc Sci Med</source>. <year>2011</year>;<volume>72</volume>(<issue>6</issue>):<fpage>919</fpage>–<lpage>927</lpage>.</citation>
</ref>
<ref id="bibr29-2168479012471945">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orofino</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Soto</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Casado</surname>
<given-names>MA</given-names>
</name>
<etal/>
</person-group>. <article-title>Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007</article-title>. <source>Appl Health Econ Health Policy</source>. <year>2010</year>;<volume>8</volume>(<issue>5</issue>):<fpage>301</fpage>–<lpage>315</lpage>.</citation>
</ref>
<ref id="bibr30-2168479012471945">
<label>30</label>
<citation citation-type="book">
<collab collab-type="author">IMS Health</collab>. <article-title>Data assets, IMS prescription data [online database]</article-title>. <comment>Accessed August 8, 2012</comment>.</citation>
</ref>
<ref id="bibr31-2168479012471945">
<label>31</label>
<citation citation-type="book">
<collab collab-type="author">
<italic>The World Medicines Situation</italic>
</collab>. <publisher-loc>Paris</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2004</year>:<fpage>151</fpage>.</citation>
</ref>
<ref id="bibr32-2168479012471945">
<label>32</label>
<citation citation-type="web">
<collab collab-type="author">Top 200 drugs for 2010 by sales</collab>. <ext-link ext-link-type="uri" xlink:href="http://www.drugs.com/top200.html">http://www.drugs.com/top200.html</ext-link>. <comment>Accessed October 1, 2011</comment>.</citation>
</ref>
<ref id="bibr33-2168479012471945">
<label>33</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Johnson</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Wichern</surname>
<given-names>DW</given-names>
</name>
</person-group>. <source>Applied Multivariate Statistical Analysis</source> (<edition>6th ed</edition>). <publisher-loc>Upper Saddle River, NJ</publisher-loc>: <publisher-name>Pearson Prentice Hall</publisher-name>; <year>2007</year>.</citation>
</ref>
<ref id="bibr34-2168479012471945">
<label>34</label>
<citation citation-type="web">
<collab collab-type="author">Orphanet</collab>: <article-title>The portal for rare diseases and orphan drugs</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.orpha.net/consor/cgi-bin/index.php">http://www.orpha.net/consor/cgi-bin/index.php</ext-link>. <comment>Accessed October 1, 2011</comment>.</citation>
</ref>
<ref id="bibr35-2168479012471945">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keyhani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hebert</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Carpenter</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>US pharmaceutical innovation in an international context</article-title>. <source>Am J Public Health</source>. <year>2010</year>;<volume>100</volume>(<issue>6</issue>):<fpage>1075</fpage>–<lpage>1080</lpage>.</citation>
</ref>
<ref id="bibr36-2168479012471945">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kneller</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>The importance of new companies for drug discovery: origins of a decade of new drugs</article-title>. <source>Nat Rev Drug Discov</source>. <year>2010</year>;<volume>9</volume>(<issue>11</issue>):<fpage>867</fpage>–<lpage>882</lpage>.</citation>
</ref>
<ref id="bibr37-2168479012471945">
<label>37</label>
<citation citation-type="web">
<collab collab-type="author">DIRLINE Directory of Health Organizations</collab>. <ext-link ext-link-type="uri" xlink:href="http://dirline.nlm.nih.gov/">http://dirline.nlm.nih.gov/</ext-link>. <comment>Accessed May 23, 2009</comment>.</citation>
</ref>
<ref id="bibr38-2168479012471945">
<label>38</label>
<citation citation-type="web">
<collab collab-type="author">Genetic Alliance</collab>. <ext-link ext-link-type="uri" xlink:href="http://www.geneticalliance.org/">http://www.geneticalliance.org/</ext-link>. <comment>Accessed November 1, 2011</comment>.</citation>
</ref>
<ref id="bibr39-2168479012471945">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Millar</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Coast</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ashcroft</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Are methicillin-resistant <italic>Staphylococcus aureus</italic> bloodstream infection targets fair to those with other types of healthcare-associated infection or cost-effective?</article-title> <source>J Hosp Infect</source>. <year>2008</year>;<volume>69</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>5</lpage>.</citation>
</ref>
<ref id="bibr40-2168479012471945">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferner</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Hughes</surname>
<given-names>DA</given-names>
</name>
</person-group>. <article-title>The problem of orphan drugs</article-title>. <source>BMJ</source>. <year>2010</year>;<volume>341</volume>:<fpage>c6456</fpage>.</citation>
</ref>
<ref id="bibr41-2168479012471945">
<label>41</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name>
<surname>Anand</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Lucrative niches: how drugs for rare diseases became lifeline for companies</article-title>. <source>Wall Street Journal</source>. <comment>November 15, 2005</comment>. <ext-link ext-link-type="uri" xlink:href="http://online.wsj.com/article/SB113202332063297223.html">http://online.wsj.com/article/SB113202332063297223.html</ext-link>.
</citation>
</ref>
<ref id="bibr42-2168479012471945">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hughes</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Tunnage</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Yeo</surname>
<given-names>ST</given-names>
</name>
</person-group>. <article-title>Drugs for exceptionally rare diseases: do they deserve special status for funding?</article-title> <source>QJM</source>. <year>2005</year>;<volume>98</volume>(<issue>11</issue>):<fpage>829</fpage>–<lpage>836</lpage>.</citation>
</ref>
<ref id="bibr43-2168479012471945">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zitter</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Managing drugs for rare genetic diseases: trends and insights</article-title>. <source>Manag Care</source>. <year>2005</year>;<volume>14</volume>(<issue>2</issue>):<fpage>52</fpage>–<lpage>54</lpage>.</citation>
</ref>
<ref id="bibr44-2168479012471945">
<label>44</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Field</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Boat</surname>
<given-names>TF</given-names>
</name>
</person-group>. <source>Rare Diseases and Orphan Products: Accelerating Research and Development</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>Institute of Medicine</publisher-name>; <year>2010</year>:<fpage>442</fpage>.</citation>
</ref>
<ref id="bibr45-2168479012471945">
<label>45</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Newhouse</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Group</surname>
<given-names>IE</given-names>
</name>
</person-group>. <source>Lessons From the Rand Health Insurance Experiment</source>. <publisher-loc>Cambridge, MA</publisher-loc>: <publisher-name>Harvard University Press</publisher-name>; <year>1993</year>:<fpage>489</fpage>.</citation>
</ref>
<ref id="bibr46-2168479012471945">
<label>46</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name>
<surname>Hooper</surname>
<given-names>CL.</given-names>
</name>
</person-group> <article-title>Pharmaceuticals: economics and regulation</article-title>. In: <source>The Concise Encyclopedia of Economics</source>. <ext-link ext-link-type="uri" xlink:href="http://www.econlib.org/library/Enc/PharmaceuticalsEconomicsandRegulation.html">http://www.econlib.org/library/Enc/PharmaceuticalsEconomicsandRegulation.html</ext-link>. <publisher-loc>Indianapolis, IN</publisher-loc>: <publisher-name>Liberty Fund Inc</publisher-name>; <year>2008</year>. <comment>Accessed June 15, 2012</comment>.</citation>
</ref>
<ref id="bibr47-2168479012471945">
<label>47</label>
<citation citation-type="web">
<collab collab-type="author">Prevalence of rare diseases: bibliographic data: [Orphanet Report Series, Rare Diseases collection]</collab>. <comment>November 2012; Number 1: Listed in alphabetical order of disease or group of diseases</comment>. <ext-link ext-link-type="uri" xlink:href="http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf">http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf</ext-link>.
</citation>
</ref>
</ref-list>
</back>
</article>